FDA approves 1st targeted drug for certain leukemia patients
U.S. regulators Friday approved the first targeted drug for certain patients with an aggressive form of leukemia. The Food and Drug Administration approved the drug for adults with acute myeloid leukemia, or AML, who have a genetic mutation called FLT3. Also OK’d was a test to identify those patients. The drug, Rydapt, known chemically as